The current landscape: what changed
- WHO lowered the global alert in September 2025 after months of progress, but warned that mpox remains a public-health concern, especially in Africa where a new Clade Ib drove outbreaks in 2024–2025. (AP News)
- U.S. watch: potential local spread of Clade I. Los Angeles County reported several Clade I cases without travel links in mid-October, with health departments and CDC urging vigilance. Clade I has been linked to more severe disease in Central and East Africa. (Los Angeles Times)
- Travel-linked Clade I cases have been identified in many countries since 2024, underscoring the need for vaccination and early care after exposures. (CDC)
Who should get vaccinated?
CDC and ACIP recommend the 2-dose JYNNEOS series for people at risk of mpox—including those with certain sexual or close-contact networks, people with recent exposures, and specific occupational groups (e.g., lab staff working with orthopoxviruses). Local criteria may expand during outbreaks. (CDC)
The vaccine you’ll hear about: JYNNEOS
- What it is: JYNNEOS (MVA-BN), a non-replicating smallpox/mpox vaccine approved by the U.S. FDA for adults at increased risk. Two doses, given 4 weeks apart. (U.S. Food and Drug Administration)
- How well it works: Real-world studies show meaningful protection—strongest after two doses—and when breakthrough infections occur, they’re typically milder than in unvaccinated people. Estimates for full (2-dose) vaccination often fall in the ~66–89% effectiveness range. (CDC)
- Boosters: CDC does not recommend more than the standard two doses at this time. (CDC)
Post-exposure vaccination: timing is everything
If you’ve had a high-risk exposure, don’t wait:
- Best: vaccinate within 4 days to prevent illness.
- Still helpful: up to 14 days post-exposure to reduce severity if infection occurs.
- In some immunocompromised patients, providers may consider vaccination even beyond 14 days after a significant exposure. (CDC)
Why vaccination still matters in 2025
- Risk hasn’t vanished. With Clade I identified in U.S. residents without travel and travel-linked cases reported globally, targeted protection remains smart. (Los Angeles Times)
- Two doses protect better than one. Data since 2022 consistently show higher effectiveness after dose 2 and milder disease in vaccinated people. (CDC)
- PEP can blunt an exposure. Timely vaccination after contact can prevent disease or reduce severity. (CDC)
Side effects & safety
JYNNEOS has a favorable safety profile compared with older smallpox vaccines (like ACAM2000). Typical effects include injection-site redness/swelling, fatigue, headache, and muscle aches; serious adverse events are uncommon. Discuss any history of severe allergies with your clinician. (PubMed Central)
Practical steps you can take today
- Haven’t started? Book dose 1 now; schedule dose 2 in 4 weeks (and get it even if you’re late). (CDC)
- Had an exposure? Seek PEP within 4 days—don’t delay. (CDC)
- Stay alert to symptoms (new rash, sores, fever, swollen nodes) and avoid close/sexual contact if symptomatic; get tested and follow isolation guidance. (Reuters)
Call us to schedule your vaccine today!
If you have any questions or would like to schedule an appointment, feel free to call us at (727) 753-7787 or message us by clicking the link below.